It is often challenging for patients with advanced cancer to make decisions surrounding end-of-life (EOL) care, in part because they have misperceptions of their prognosis. A study assessed how a patients’ perception of their prognosis may affect EOL outcomes. The results were presented during the 2021 ASCO Annual Meeting. The researchers performed a secondary analysis using data from a palliative care intervention trial in patients with newly diagnosed incurable lung and non-colorectal gastrointestinal cancer. Patients completed the Prognosis and Treatment Perceptions Questionnaire at baseline, week 12, and week 24. The assessment that was performed closest to the ...
Advertisement
For patients with myelofibrosis, the only curative treatment option is allogenic hematopoietic cell transplant (allo-HCT).
A study presented during ASCO 2021 reviewed a program to streamline discussions surrounding fertility preservation options.
Acute panmyelosis with myelofibrosis (APMF) is a rare disease with limited population-based data.
A retrospective study assessed how advanced care planning affected end-of-life outcomes in patients who underwent allo-HCT.
Satisfaction with telehealth is on the rise. However, differences persist by demographic.
Final analysis included 104,135 matched pairs of patients with and without cancer-related diarrhea.
The results were presented during the 2021 ASCO Annual Meeting.
The researchers queried PubMed, EMBASE, ASCO, and San Antonio Breast Cancer Symposium meeting abstracts.
Researchers identified patients with Philadelphia-negative MPN and compared patients with versus without sepsis.
Data were collected on 541 patients with incurable solid tumor or lymphoma considering any line of cancer treatment.
Ph-like ALL is a high-risk subgroup with increased prevalence in younger adults.
PROs are outcomes directly reported by the patient without interpretation from a clinician.
The study included patients diagnosed with cancer and PCR-confirmed COVID-19.
The results were presented during the 2021 ASCO Annual Meeting.
A study presented during ASCO 2021 assessed the prevalence of germline testing at a breast cancer survivorship clinic.
The lives of patients who undergo hematopoietic stem cell transplantation (HSCT) change in several ways.
Final analysis included 138 patients who underwent lung metastasectomy.
Advertisement
